G3 Pharmaceuticals Signs Exclusive License and Option Agreement for Treating Diastolic Heart Failure (HFpEF) by Inhibiting Galectin-3

Galectin-3 inhibitors offer new hope for an important unmet medical need BURLINGTON, Mass., Oct. 30, 2018 -- (Healthcare Sales & Marketing Network) -- G3 Pharmaceuticals, a development-stage biopharmaceutical company located in Burlington, MA, today an... Biopharmaceuticals, Cardiology, Licensing G3 Pharmaceuticals, galectin-3, diastolic heart failure, heart failure
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news